Departement
Klinische Forschung
Achtung: Diese Seite kann nur von Administratoren besucht werden, da Sie nicht freigeschalten wurde.
Zurück
Publications Wild Damian

Peptide Receptor Radionuclide Therapy in Merkel Cell Carcinoma: A Comprehensive Review.

Askari E; Moghadam SZ; Wild D; Delpassand E; Baldari S; Nilica B; Hartrampf PE; Kong G; Grana CM; Alexander Walter M; Capoccetti F; Kasi PM; Strosberg J. Journal of nuclear medicine technology. 2023.

ENETS standardized (synoptic) reporting for molecular imaging studies in neuroendocrine tumours.

Hicks RJ; Dromain C; de Herder WW; Costa FP; Deroose CM; Frilling A; Koumarianou A; Krenning EP; Raymond E; Bodei L; Sorbye H; Welin S; Wiedenmann B; Wild D; Howe JR; Yao J; O'Toole D; Sundin A; Prasad V. Journal of Neuroendocrinology. 2022.

Factors Contributing to Tumor Shrinkage after Peptide Receptor Radionuclide Therapy in Patients with Unresectable Neuroendocrine Tumors

Hasegawa S.; Kobayashi N.; Wild D.; Kaul F.; Okubo N.; Suzuki A.; Kurita Y.; Takano S.; Nakajima A.; Ichikawa Y.. Cancers. 2022.

Molecular Imaging in neuroendocrine neoplasias.

Christ E; Wild D; Refardt J. Presse medicale (Paris, France : 1983). 2022.

Molecular Imaging of Neuroendocrine Neoplasms

Refardt J.; Hofland J.; Wild D.; Christ E.. Journal of Clinical Endocrinology and Metabolism. 2022.

Quantitative myocardial perfusion (82)Rb-PET assessed by hybrid PET/coronary-CT: Normal values and diagnostic performance.

Freitag MT; Bremerich J; Wild D; Haaf P; Zellweger MJ; Caobelli F. Journal of Nuclear Cardiology. 2022.

Radiolabeled Somatostatin Analogs—A Continuously Evolving Class of Radiopharmaceuticals

Fani M.; Mansi R.; Nicolas G.P.; Wild D.. Cancers. 2022.

Targeted colonic release formulations of mesalazine - A clinical pharmaco-scintigraphic proof-of-concept study in healthy subjects and patients with mildly active ulcerative colitis.

Varum F; Thorne H; Bravo R; Gilgen D; Hartig C; Nicolas GP; Wild D; Liakoni E; Haschke M. International journal of pharmaceutics. 2022.

Accuracy comparison of various quantitative [(99m)Tc]Tc-DPD SPECT/CT reconstruction techniques in patients with symptomatic hip and knee joint prostheses.

Braun M; Cachovan M; Kaul F; Caobelli F; Bäumer M; Hans Vija A; Pagenstert G; Wild D; Kretzschmar M. EJNMMI Research. 2021.

Colonic delivery of metronidazole-loaded capsules for local treatment of bacterial infections: A clinical pharmacoscintigraphy study.

Preisig D; Varum F; Bravo R; Hartig C; Spleiss J; Abbes S; Caobelli F; Wild D; Puchkov M; Huwyler J; Haschke M. European Journal of Pharmaceutics and Biopharmaceutics. 2021.

Consensus on molecular imaging and theranostics in neuroendocrine neoplasms.

Ambrosini V; Kunikowska J; Baudin E; Bodei L; Bouvier C; Capdevila J; Cremonesi M; de Herder WW; Dromain C; Falconi M; Fani M; Fanti S; Hicks RJ; Kabasakal L; Kaltsas G; Lewington V; Minozzi S; Cinquini M; Öberg K; Oyen WJG; O'Toole D; Pavel M; Ruszniewski P; Scarpa A; Strosberg J; Sundin A; Taïeb D; Virgolini I; Wild D; Herrmann K; Yao J. European Journal of Cancer. 2021.

Glucagon-like Peptide-1 Receptor as Emerging Target: Will It Make It to the Clinic?

Wild D; Antwi K; Fani M; Christ ER. Journal of Nuclear Medicine. 2021.

Investigating difficult to detect pancreatic lesions: Characterization of benign pancreatic islet cell tumors using multiparametric pancreatic 3-T MRI.

Antwi K; Wiesner P; Merkle EM; Zech CJ; Boll DT; Wild D; Christ E; Heye T. PLoS ONE. 2021.

Metastatic Medullary Thyroid Cancer: The Role of 68Gallium-DOTA-Somatostatin Analogue PET/CT and Peptide Receptor Radionuclide Therapy.

Hayes AR; Crawford A; Al Riyami K; Tang C; Bomanji J; Baldeweg SE; Wild D; Morganstein D; Harry A; Grozinsky-Glasberg S; Oleinikov K; Khoo B; Caplin ME; Nicolas GP; Grossman AB. Journal of Clinical Endocrinology and Metabolism. 2021.

New Directions in Imaging Neuroendocrine Neoplasms.

Refardt J; Hofland J; Wild D; Christ E. Current oncology reports. 2021.

Retrospective study of peptide receptor radionuclide therapy for Japanese patients with advanced neuroendocrine tumors.

Kobayashi N; Wild D; Kaul F; Shimamura T; Takano S; Takeda Y; Okubo N; Suzuki A; Tokuhisa M; Ichikawa Y. Journal of Hepato-Biliary-Pancreatic Sciences. 2021.

Safety and efficacy of peptide-receptor radionuclide therapy in elderly neuroendocrine tumor patients

Theiler D.; Cattaneo M.; Dierickx L.O.; Igaz P.; Grozinsky-Glasberg S.; Bournaud C.; O'dorisio T.; Sue O'Dorisio M.; Wild D.; Christ E.; Nicolas G.P.. Cancers. 2021.

Theranostics in neuroendocrine tumors: an overview of current approaches and future challenges.

Refardt J; Hofland J; Kwadwo A; Nicolas GP; Rottenburger C; Fani M; Wild D; Christ E. Reviews in Endocrine and Metabolic Disorders. 2021.

Brunner's Gland Hyperplasia in a Patient after Roux-Y Gastric Bypass: An Important Pitfall in GLP-1 Receptor Imaging.

Hepprich M; Antwi K; Waser B; Reubi JC; Wild D; Christ ER. . 2020.

Cholecystokinin 2 Receptor Agonist (177)Lu-PP-F11N for Radionuclide Therapy of Medullary Thyroid Carcinoma: Results of the Lumed Phase 0a Study.

Rottenburger C; Nicolas GP; McDougall L; Kaul F; Cachovan M; Vija AH; Schibli R; Geistlich S; Schumann A; Rau T; Glatz K; Behe M; Christ ER; Wild D. Journal of Nuclear Medicine. 2020.

Comparison of [(18)F]FDG PET/CT with magnetic resonance imaging for the assessment of human brown adipose tissue activity.

Fischer JGW; Maushart CI; Becker AS; Müller J; Madoerin P; Chirindel A; Wild D; Ter Voert EEGW; Bieri O; Burger I; Betz MJ. EJNMMI Research. 2020.

Incremental value of high-frequency QRS analysis for diagnosis and prognosis in suspected exercise-induced myocardial ischaemia.

Schaerli N; Abächerli R; Walter J; Honegger U; Puelacher C; Rinderknecht T; Müller D; Boeddinghaus J; Nestelberger T; Strebel I; Badertscher P; du Fay de Lavallaz J; Twerenbold R; Wussler D; Hofer J; Leber R; Kaiser C; Osswald S; Wild D; Zellweger MJ; Mueller C; Reichlin T. European heart journal. Acute cardiovascular care. 2020.

Innovative imaging of insulinoma: the end of sampling? A review.

Christ E; Antwi K; Fani M; Wild D. Endocrine-related cancer. 2020.

Peptide Receptor Radionuclide Therapy for a Phosphaturic Mesenchymal Tumor.

Häfliger S; Seidel AK; Schoch E; Reichmann J; Wild D; Steinmann-Schwager S; Pless M. . 2020.

Pitfalls in the Detection of Insulinomas With Glucagon-Like Peptide-1 Receptor Imaging.

Antwi K; Hepprich M; Müller NA; Reubi JC; Fani M; Rottenburger C; Nicolas G; Kaul F; Christ ER; Wild D. Clinical Nuclear Medicine. 2020.

Quantitative (99m)Tc-DPD SPECT/CT in patients with suspected ATTR cardiac amyloidosis: Feasibility and correlation with visual scores.

Caobelli F; Braun M; Haaf P; Wild D; Zellweger MJ. Journal of Nuclear Cardiology. 2020.

68Ga-Exendin-4 PET/CT Detects Insulinomas in Patients With Endogenous Hyperinsulinemic Hypoglycemia in MEN-1.

Antwi K; Nicolas G; Fani M; Heye T; Pattou F; Grossman A; Chanson P; Reubi JC; Perren A; Gloor B; Vogt DR; Wild D; Christ E. Journal of Clinical Endocrinology and Metabolism. 2019.

Eruption of Metastatic Paraganglioma After Successful Therapy with (177)Lu/(90)Y-DOTATOC and (177)Lu-DOTATATE.

Wolf KI; Jha A; van Berkel A; Wild D; Janssen I; Millo CM; Janssen MJR; Gonzales MK; Timmers HJKM; Pacak K. . 2019.

In Vivo Biokinetics of (177)Lu-OPS201 in Mice and Pigs as a Model for Predicting Human Dosimetry.

Beykan S; Fani M; Jensen SB; Nicolas G; Wild D; Kaufmann J; Lassmann M. Contrast media & molecular imaging. 2019.

Molecular imaging for neuroendocrine tumours.

Antwi K; Nicolas G; Wild D; Christ E. Swiss medical weekly. 2019.

Prevalence and determinants of exercise-induced left ventricular dysfunction in patients with coronary artery disease.

Honegger U; Walter JE; Mueller D; Puelacher C; Schaerli N; Twerenbold R; Badertscher P; Boeddinghaus J; Nestelberger T; du Fay de Lavallaz J; Wussler D; Pfister O; Jeger R; Kaiser C; Wild D; Schmidt-Trucksäss A; Reichlin T; Mueller C. European Journal of Clinical Investigation. 2019.

Succinylated Gelatin Improves the Theranostic Potential of Radiolabeled Exendin-4 in Insulinoma Patients.

Buitinga M; Jansen T; van der Kroon I; Woliner-van der Weg W; Boss M; Janssen M; Aarntzen E; Béhé M; Wild D; Visser E; Brom M; Gotthardt M. Journal of Nuclear Medicine. 2019.

Targeting of the Cholecystokinin-2 Receptor with the Minigastrin Analog (177)Lu-DOTA-PP-F11N: Does the Use of Protease Inhibitors Further Improve In Vivo Distribution?

Sauter AW; Mansi R; Hassiepen U; Muller L; Panigada T; Wiehr S; Wild AM; Geistlich S; Béhé M; Rottenburger C; Wild D; Fani M. Journal of Nuclear Medicine. 2019.

Volume Replacement Fluid Demarks Benign Insulinoma With 68Ga-DOTA-Exendin-4 PET/CT.

Antwi K; Nicolas G; Fani M; Christ E; Wild D. Clinical Nuclear Medicine. 2019.

[Treatment of Advanced Prostate Carcinoma - an Interdisciplinary Recommendation].

Omlin A; Spahn M; Beyer J; Eberli D; Gillessen S; Jochum W; Kueng M; Nitzsche E; Rentsch CA; Roggero E; Schmid HP; Stenner F; Templeton AJ; Wild D; Wyler S; Zwahlen D; Cathomas R. Praxis. 2018.

Automatically computed ECG algorithm for the quantification of myocardial scar and the prediction of mortality.

Badertscher P; Strebel I; Honegger U; Schaerli N; Mueller D; Puelacher C; Wagener M; Abächerli R; Walter J; Sabti Z; Sazgary L; Marbot S; du Fay de Lavallaz J; Twerenbold R; Boeddinghaus J; Nestelberger T; Kozhuharov N; Breidthardt T; Shrestha S; Flores D; Schumacher C; Wild D; Osswald S; Zellweger MJ; Mueller C; Reichlin T. Clinical Research in Cardiology. 2018.

Clinical presentation of 54 patients with endogenous hyperinsulinaemic hypoglycaemia: a neurological chameleon (observational study).

Valente LG; Antwi K; Nicolas GP; Wild D; Christ E. Swiss medical weekly. 2018.

Combining high-sensitivity cardiac troponin and B-type natriuretic peptide in the detection of inducible myocardial ischemia.

Puelacher C; Wagener M; Honegger U; Assadian M; Schaerli N; Mueller D; Strebel I; Twerenbold R; Boeddinghaus J; Nestelberger T; Wildi K; Sabti Z; Sazgary L; Badertscher P; du Fay de Lavallaz J; Marbot S; Kaiser C; Wild D; Zellweger MJ; Reichlin T; Mueller C. Clinical Biochemistry. 2018.

Comparison of glucagon-like peptide-1 receptor (GLP-1R) PET/CT, SPECT/CT and 3T MRI for the localisation of occult insulinomas: evaluation of diagnostic accuracy in a prospective crossover imaging study.

Antwi K; Fani M; Heye T; Nicolas G; Rottenburger C; Kaul F; Merkle E; Zech CJ; Boll D; Vogt DR; Gloor B; Christ E; Wild D. European Journal of Nuclear Medicine and Molecular Imaging. 2018.

Direct Comparison of Cardiac Troponin T and I Using a Uniform and a Sex-Specific Approach in the Detection of Functionally Relevant Coronary Artery Disease.

Mueller D; Puelacher C; Honegger U; Walter JE; Badertscher P; Schaerli N; Strebel I; Twerenbold R; Boeddinghaus J; Nestelberger T; Hollenstein C; du Fay de Lavallaz J; Jeger R; Kaiser C; Wild D; Rentsch K; Buser A; Zellweger M; Reichlin T; Mueller C. Clinical chemistry. 2018.

Prospective Validation of a Biomarker-Based Rule Out Strategy for Functionally Relevant Coronary Artery Disease.

Walter JE; Honegger U; Puelacher C; Mueller D; Wagener M; Schaerli N; Strebel I; Twerenbold R; Boeddinghaus J; Nestelberger T; Sazgary L; Marbot S; du Fay de Lavallaz J; Kaiser C; Osswald S; Wild D; Rentsch K; Zellweger M; Reichlin T; Mueller C. Clinical chemistry. 2018.

Reply: Advantages and Limits of Targeted Radionuclide Therapy with Somatostatin Antagonists.

Nicolas GP; Wild D; Fani M. Journal of Nuclear Medicine. 2018.

Safety, Biodistribution, and Radiation Dosimetry of (68)Ga-OPS202 in Patients with Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Phase I Imaging Study.

Nicolas GP; Beykan S; Bouterfa H; Kaufmann J; Bauman A; Lassmann M; Reubi JC; Rivier JEF; Maecke HR; Fani M; Wild D. Journal of Nuclear Medicine. 2018.

Sensitivity Comparison of (68)Ga-OPS202 and (68)Ga-DOTATOC PET/CT in Patients with Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Phase II Imaging Study.

Nicolas GP; Schreiter N; Kaul F; Uiters J; Bouterfa H; Kaufmann J; Erlanger TE; Cathomas R; Christ E; Fani M; Wild D. Journal of Nuclear Medicine. 2018.

Biodistribution, Pharmacokinetics, and Dosimetry of (177)Lu-, (90)Y-, and (111)In-Labeled Somatostatin Receptor Antagonist OPS201 in Comparison to the Agonist (177)Lu-DOTATATE: The Mass Effect.

Nicolas GP; Mansi R; McDougall L; Kaufmann J; Bouterfa H; Wild D; Fani M. Journal of Nuclear Medicine. 2017.

Diagnostic and Prognostic Value of Lead aVR During Exercise Testing in Patients Suspected of Having Myocardial Ischemia.

Wagener M; Abächerli R; Honegger U; Schaerli N; Prêtre G; Twerenbold R; Puelacher C; Sunier G; Reddiess P; Rubini Gimenez M; Wildi K; Boeddinghaus J; Nestelberger T; Badertscher P; Sabti Z; Schmid R; Leber R; Widmer DF; Shrestha S; Strebel I; Wild D; Osswald S; Zellweger M; Mueller C; Reichlin T. American Journal of Cardiology. 2017.

Diagnostic value of ST-segment deviations during cardiac exercise stress testing: Systematic comparison of different ECG leads and time-points.

Puelacher C; Wagener M; Abächerli R; Honegger U; Lhasam N; Schaerli N; Prêtre G; Strebel I; Twerenbold R; Boeddinghaus J; Nestelberger T; Rubini Giménez M; Hillinger P; Wildi K; Sabti Z; Badertscher P; Cupa J; Kozhuharov N; du Fay de Lavallaz J; Freese M; Roux I; Lohrmann J; Leber R; Osswald S; Wild D; Zellweger MJ; Mueller C; Reichlin T. International Journal of Cardiology. 2017.

Efficacy of Peptide Receptor Radionuclide Therapy in a United States-Based Cohort of Metastatic Neuroendocrine Tumor Patients: Single-Institution Retrospective Analysis

Katona B.W.; Roccaro G.A.; Soulen M.C.; Yang Y.-X.; Bennett B.J.; Riff B.P.; Glynn R.A.; Wild D.; Nicolas G.P.; Pryma D.A.; Teitelbaum U.R.; Metz D.C.. Pancreas. 2017.

PET/CT Imaging of Unstable Carotid Plaque with (68)Ga-Labeled Somatostatin Receptor Ligand.

Wan MYS; Endozo R; Michopoulou S; Shortman R; Rodriguez-Justo M; Menezes L; Yusuf S; Richards T; Wild D; Waser B; Reubi JC; Groves A. Journal of Nuclear Medicine. 2017.

Somatostatin Receptor Antagonists for Imaging and Therapy.

Fani M; Nicolas GP; Wild D. Journal of Nuclear Medicine. 2017.

The Spatial Relationship between Apparent Diffusion Coefficient and Standardized Uptake Value of (18)F-Fluorodeoxyglucose Has a Crucial Influence on the Numeric Correlation of Both Parameters in PET/MRI of Lung Tumors.

Sauter AW; Stieltjes B; Weikert T; Gatidis S; Wiese M; Klarhöfer M; Wild D; Lardinois D; Bremerich J; Sommer G. Contrast media & molecular imaging. 2017.

[Recurrent hypoglycemia due to an occult insulinoma].

Breuer TG; Breuer HL; Menge BA; Giese A; Uhl W; Schmidt WE; Tannapfel A; Wild D; Nauck MA; Meier JJ. Der Internist. 2016.

Application of Ga(68) -DOTA-exendin-4 PET/CT to localize an occult insulinoma.

Cuthbertson DJ; Banks M; Khoo B; Antwi K; Christ E; Campbell F; Raraty M; Wild D. Clinical Endocrinology. 2016.

Clinical benefit of high-sensitivity cardiac troponin I in the detection of exercise-induced myocardial ischemia.

Lee G; Twerenbold R; Tanglay Y; Reichlin T; Honegger U; Wagener M; Jaeger C; Rubini Gimenez M; Hochgruber T; Puelacher C; Radosavac M; Kreutzinger P; Stallone F; Hillinger P; Krivoshei L; Herrmann T; Mayr R; Freese M; Wild D; Rentsch KM; Todd J; Osswald S; Zellweger MJ; Mueller C. American Heart Journal. 2016.

Direct comparison of cardiac troponin I and cardiac troponin T in the detection of exercise-induced myocardial ischemia.

Sou SM; Puelacher C; Twerenbold R; Wagener M; Honegger U; Reichlin T; Schaerli N; Pretre G; Abächerli R; Jaeger C; Rubini Gimenez M; Wild D; Rentsch KM; Zellweger MJ; Mueller C. Clinical Biochemistry. 2016.

Gastroenteropancreatic neuroendocrine tumours (GEP-NET) - Imaging and staging.

Baumann T; Rottenburger C; Nicolas G; Wild D. Best practice & research. Clinical endocrinology & metabolism. 2016.

Association between cartilage degeneration and subchondral bone remodeling in patients with knee osteoarthritis comparing MRI and (99m)Tc-DPD-SPECT/CT.

Maas O; Joseph GB; Sommer G; Wild D; Kretzschmar M. Osteoarthritis and Cartilage. 2015.

Delayed release of brain natriuretic peptide to identify myocardial ischaemia.

Zürcher S; Honegger U; Wagener M; Lee G; Stallone F; Marxer T; Puelacher C; Schumacher C; Sou SM; Twerenbold R; Reichlin T; Hochgruber T; Tanglay Y; Freese M; Wild D; Rentsch K; Osswald S; Zellweger M; Mueller C. European Journal of Clinical Investigation. 2015.

Incremental value of a single high-sensitivity cardiac troponin I measurement to rule out myocardial ischemia.

Tanglay Y; Twerenbold R; Lee G; Wagener M; Honegger U; Puelacher C; Reichlin T; Mann S; Druey S; Hochgruber T; Zürcher S; Radosavac M; Kreutzinger P; Pretre G; Stallone F; Hillinger P; Jaeger C; Rubini Gimenez M; Freese M; Wild D; Rentsch K; Osswald S; Zellweger MJ; Mueller C. The American journal of medicine. 2015.

Localization of Hidden Insulinomas with ⁶⁸Ga-DOTA-Exendin-4 PET/CT: A Pilot Study.

Antwi K; Fani M; Nicolas G; Rottenburger C; Heye T; Reubi JC; Gloor B; Christ E; Wild D. Journal of Nuclear Medicine. 2015.

Non-invasive nuclear myocardial perfusion imaging improves the diagnostic yield of invasive coronary angiography

Buechel R.R.; Kaufmann B.A.; Tobler D.; Wild D.; Zellweger M.J.. European heart journal. Cardiovascular Imaging. 2015.

Peptide Receptor Radionuclide Therapy-Induced Hepatotoxicity in Patients With Metastatic Neuroendocrine Tumors.

Riff BP; Yang YX; Soulen MC; Pryma DA; Bennett B; Wild D; Nicolas G; Teitelbaum UR; Metz DC. Clinical Nuclear Medicine. 2015.

Preoperative Glucagon-like peptide-1 receptor imaging reduces surgical trauma and pancreatic tissue loss in insulinoma patients: a report of three cases.

Wenning AS; Kirchner P; Antwi K; Fani M; Wild D; Christ E; Gloor B. Patient safety in surgery. 2015.

Preoperative localization of adult nesidioblastosis using (68)Ga-DOTA-exendin-4-PET/CT.

Christ,Emanuel; Wild,Damian; Antwi,Kwadwo; Waser,Beatrice; Fani,Melpomeni; Schwanda,Stefanie; Heye,Tobias; Schmid,Christoph; Baer,Hans Ulrich; Perren,Aurel; Reubi,Jean Claude. Endocrine. 2015.

Preoperative localization of adult nesidioblastosis using ⁶⁸Ga-DOTA-exendin-4-PET/CT.

Christ E; Wild D; Antwi K; Waser B; Fani M; Schwanda S; Heye T; Schmid C; Baer HU; Perren A; Reubi JC. Endocrine. 2015.

B-type natriuretic peptide and clinical judgment in the detection of exercise-induced myocardial ischemia.

Lee G; Sou SM; Twerenbold R; Reichlin T; Oshima S; Hochgruber T; Zürcher S; Matter D; Tanglay Y; Freese M; Honegger U; Wild D; Rentsch K; Osswald S; Zellweger MJ; Mueller C. The American journal of medicine. 2014.

Comparison of somatostatin receptor agonist and antagonist for peptide receptor radionuclide therapy: a pilot study.

Wild D; Fani M; Fischer R; Del Pozzo L; Kaul F; Krebs S; Fischer R; Rivier JE; Reubi JC; Maecke HR; Weber WA. Journal of Nuclear Medicine. 2014.

Prognostic value of "routine" cardiac stress imaging 5 years after percutaneous coronary intervention: the prospective long-term observational BASKET (Basel Stent Kosteneffektivitäts Trial) LATE IMAGING study.

Zellweger MJ; Fahrni G; Ritter M; Jeger RV; Wild D; Buser P; Kaiser C; Osswald S; Pfisterer ME; BASKET Investigators. JACC: Cardiovascular Interventions. 2014.

Synergism of peptide receptor-targeted Auger electron radiation therapy with anti-angiogenic compounds in a mouse model of neuroendocrine tumors

Wicki A.; Wild D.; Pretre V.; Mansi R.; Orleth A.; Reubi J.-C.; Rochlitz C.; Mamot C.; Macke H.R.; Christofori G.. EJNMMI Research. 2014.

Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors.

Wild D; Bomanji JB; Benkert P; Maecke H; Ell PJ; Reubi JC; Caplin ME. Journal of Nuclear Medicine. 2013.

Glucagon-like peptide-1 receptor imaging for the localisation of insulinomas: a prospective multicentre imaging study.

Christ E; Wild D; Ederer S; Béhé M; Nicolas G; Caplin ME; Brändle M; Clerici T; Fischli S; Stettler C; Ell PJ; Seufert J; Gloor B; Perren A; Reubi JC; Forrer F. The Lancet Diabetes and Endocrinology. 2013.

Glucagon-like peptide-1 receptor overexpression in cancer and its impact on clinical applications

Korner M.; Christ E.; Wild D.; Reubi J.C.. Frontiers in endocrinology. 2012.

Novel positron emission tomography/computed tomography of diffuse parenchymal lung disease combining a labeled somatostatin receptor analogue and 2-deoxy-2[18F]fluoro-D-glucose.

Win T; Screaton NJ; Porter J; Endozo R; Wild D; Kayani I; Dickson J; Shortman RI; Reubi JC; Ell PJ; Groves AM. Molecular Imaging. 2012.

Alpha- versus beta-particle radiopeptide therapy in a human prostate cancer model (213Bi-DOTA-PESIN and 213Bi-AMBA versus 177Lu-DOTA-PESIN).

Wild D; Frischknecht M; Zhang H; Morgenstern A; Bruchertseifer F; Boisclair J; Provencher-Bolliger A; Reubi JC; Maecke HR. Cancer Research. 2011.

First clinical evidence that imaging with somatostatin receptor antagonists is feasible.

Wild D; Fani M; Behe M; Brink I; Rivier JE; Reubi JC; Maecke HR; Weber WA. Journal of Nuclear Medicine. 2011.

Glucagon-like peptide-1 versus somatostatin receptor targeting reveals 2 distinct forms of malignant insulinomas

Wild D.; Christ E.; Caplin M.E.; Kurzawinski T.R.; Forrer F.; Brandle M.; Seufert J.; Weber W.A.; Bomanji J.; Perren A.; Ell P.J.; Reubi J.C.. Journal of Nuclear Medicine. 2011.

'Running on empty'.

Wild D; Theodoraki A; Kurzawinski TR; Bomanji J; Reubi JC; Khan R; Bouloux P; Khoo B. European Journal of Nuclear Medicine and Molecular Imaging. 2010.

Distribution pattern of 68Ga-DOTATATE in disease-free patients.

Shastry M; Kayani I; Wild D; Caplin M; Visvikis D; Gacinovic S; Reubi JC; Bomanji JB. NUCLEAR MEDICINE COMMUNICATIONS. 2010.

Exendin-4-based radiopharmaceuticals for glucagonlike peptide-1 receptor PET/CT and SPECT/CT.

Wild D; Wicki A; Mansi R; Béhé M; Keil B; Bernhardt P; Christofori G; Ell PJ; Mäcke HR. Journal of Nuclear Medicine. 2010.

GLP-1-receptor scanning for imaging of human beta cells transplanted in muscle.

Pattou F; Kerr-Conte J; Wild D. New England Journal of Medicine. 2010.

Glucagonlike peptide-1 receptor: an example of translational research in insulinomas: a review.

Christ E; Wild D; Reubi JC. Endocrinology and metabolism clinics of North America. 2010.

Phaeochromocytoma and thrombotic microangiopathy: favourable outcome despite advanced renal failure.

Schweizer H; Boehm J; Winterer JT; Wild D; Neumann HP; Wiech T; Stubanus M; Kuehn EW. Journal of clinical pathology. 2010.

Glucagon-like peptide-1 receptor imaging for localization of insulinomas

Christ E.; Wild D.; Forrer F.; Brandle M.; Sahli R.; Clerici T.; Gloor B.; Martius F.; Maecke H.; Reubi J.C.. Journal of Clinical Endocrinology and Metabolism. 2009.

Glucagon-like peptide 1-receptor scans to localize occult insulinomas.

Wild D; Mäcke H; Christ E; Gloor B; Reubi JC. New England Journal of Medicine. 2008.

New pansomatostatin ligands and their chelated versions: affinity profile, agonist activity, internalization, and tumor targeting.

Ginj M; Zhang H; Eisenwiener KP; Wild D; Schulz S; Rink H; Cescato R; Reubi JC; Maecke HR. Clinical Cancer Research. 2008.

[Lys40(Ahx-DTPA-111In)NH2]-Exendin-4 is a highly efficient radiotherapeutic for glucagon-like peptide-1 receptor-targeted therapy for insulinoma.

Wicki A; Wild D; Storch D; Seemayer C; Gotthardt M; Behe M; Kneifel S; Mihatsch MJ; Reubi JC; Mäcke HR; Christofori G. Clinical Cancer Research. 2007.

DOTA-PESIN, a DOTA-conjugated bombesin derivative designed for the imaging and targeted radionuclide treatment of bombesin receptor-positive tumours.

Zhang H; Schuhmacher J; Waser B; Wild D; Eisenhut M; Reubi JC; Maecke HR. European Journal of Nuclear Medicine and Molecular Imaging. 2007.

[Lys40(Ahx-DTPA-111In)NH2]exendin-4, a very promising ligand for glucagon-like peptide-1 (GLP-1) receptor targeting

Wild D.; Behe M.; Wicki A.; Storch D.; Waser B.; Gotthardt M.; Keil B.; Christofori G.; Reubi J.C.; Macke H.R.. Journal of Nuclear Medicine. 2006.

[Lys40(Ahx-DTPA-111In)NH2]exendin-4, a very promising ligand for glucagon-like peptide-1 (GLP-1) receptor targeting.

Wild D; Béhé M; Wicki A; Storch D; Waser B; Gotthardt M; Keil B; Christofori G; Reubi JC; Mäcke HR. Journal of Nuclear Medicine. 2006.

Coregistered iodine-131 single photon emission computed tomography/computed tomography reveals dedifferentiation in a metastatic follicular thyroid carcinoma.

Walter MA; Wild D; Rasch H; Müller-Brand J; Müller B; Bilz S. Thyroid. 2006.

In-line (18)F-fluorodeoxyglucose positron emission tomography with computed tomography (PET/CT) in patients with carcinoma of the sinus/nasal area and orbit.

Wild D; Eyrich GK; Ciernik IF; Stoeckli SJ; Schuknecht B; Goerres GW. Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery. 2006.

Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors.

Ginj M; Zhang H; Waser B; Cescato R; Wild D; Wang X; Erchegyi J; Rivier J; Mäcke HR; Reubi JC. Proceedings of the National Academy of Sciences of the United States of America. 2006.

Use of B-type natriuretic peptide in the detection of myocardial ischemia

Staub D.; Nusbaumer C.; Zellweger M.J.; Jonas N.; Wild D.; Pfisterer M.E.; Mueller-Brand J.; Perruchoud A.P.; Mueller C.. American Heart Journal. 2006.

68Ga-DOTANOC: a first compound for PET imaging with high affinity for somatostatin receptor subtypes 2 and 5.

Wild D; Mäcke HR; Waser B; Reubi JC; Ginj M; Rasch H; Müller-Brand J; Hofmann M. European Journal of Nuclear Medicine and Molecular Imaging. 2005.

Use of N-terminal pro-B-type natriuretic peptide to detect myocardial ischemia

Staub D.; Jonas N.; Zellweger M.J.; Nusbaumer C.; Wild D.; Pfisterer M.E.; Mueller-Brand J.; Perruchoud A.P.; Mueller C.. The American journal of medicine. 2005.

Uptake of 18F-fluorocholine, 18F-fluoroethyl-L-tyrosine, and 18F-FDG in acute cerebral radiation injury in the rat: implications for separation of radiation necrosis from tumor recurrence.

Spaeth N; Wyss MT; Weber B; Scheidegger S; Lutz A; Verwey J; Radovanovic I; Pahnke J; Wild D; Westera G; Weishaupt D; Hermann DM; Kaser-Hotz B; Aguzzi A; Buck A. Journal of Nuclear Medicine. 2004.

DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals.

Wild D; Schmitt JS; Ginj M; Mäcke HR; Bernard BF; Krenning E; De Jong M; Wenger S; Reubi JC. European Journal of Nuclear Medicine and Molecular Imaging. 2003.

Quantitative cerebral blood flow measurements in the rat using a beta-probe and H2 15O.

Weber B; Späth N; Wyss M; Wild D; Burger C; Stanley R; Buck A. Journal of Cerebral Blood Flow and Metabolism. 2003.